| P50 | author | Ralph A. DeFronzo | Q58689309 |
| | Eleuterio Ferrannini | Q59193801 |
| P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
| | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| | Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults | Q22250906 |
| | Cardiovascular outcomes in trials of oral diabetes medications: a systematic review | Q22253058 |
| | Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus | Q24243196 |
| | Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 |
| | Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies | Q24608301 |
| | Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 |
| | Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease | Q26866392 |
| | Residual macrovascular risk in 2013: what have we learned? | Q26996039 |
| | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| | The target of metformin in type 2 diabetes | Q28249761 |
| | Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 |
| | Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Q28281870 |
| | A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes | Q28282265 |
| | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| | Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 |
| | Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes | Q28295311 |
| | Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 |
| | Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 |
| | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 |
| | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 |
| | Effects of intensive glucose lowering in type 2 diabetes | Q29547736 |
| | 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 |
| | Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 |
| | Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 |
| | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 |
| | HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study | Q30700439 |
| | Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial | Q30840447 |
| | Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo | Q36635727 |
| | Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis | Q36649277 |
| | Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease | Q36667186 |
| | Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes | Q36730207 |
| | Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease | Q36782688 |
| | Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. | Q36792608 |
| | Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies | Q36807402 |
| | Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). | Q36914416 |
| | Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. | Q36945300 |
| | Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). | Q37106424 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes | Q37193454 |
| | Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 |
| | Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates | Q37251096 |
| | The incretin system and its role in type 2 diabetes mellitus | Q37266863 |
| | Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. | Q37322877 |
| | Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? | Q37395298 |
| | Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study | Q37403220 |
| | Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 |
| | Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors | Q37505281 |
| | Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 |
| | Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? | Q37535457 |
| | In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion | Q37577126 |
| | Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? | Q37792839 |
| | Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us? | Q37803259 |
| | Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review | Q37813161 |
| | Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies | Q37824904 |
| | Pathophysiology of prediabetes | Q37833737 |
| | Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. | Q37878715 |
| | Preservation of β-cell function: the key to diabetes prevention | Q37893344 |
| | Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? | Q37898749 |
| | The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury | Q37926558 |
| | Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states | Q37962246 |
| | DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials | Q37971194 |
| | SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 |
| | Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. | Q38031093 |
| | Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial | Q38085534 |
| | Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). | Q31120403 |
| | Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria | Q31931889 |
| | Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 |
| | Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study | Q33487709 |
| | Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study | Q33508039 |
| | Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes | Q33562235 |
| | Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) | Q33764951 |
| | An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. | Q33786150 |
| | Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 |
| | The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis | Q33873053 |
| | Hypoglycemia, diabetes, and cardiovascular events | Q33873251 |
| | Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 |
| | Diabetes mellitus, fasting glucose, and risk of cause-specific death | Q33945937 |
| | Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis | Q34031108 |
| | DPP-4 inhibitors and lipids: systematic review and meta-analysis | Q34116689 |
| | Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data | Q34128612 |
| | Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study | Q34158078 |
| | Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program | Q34195798 |
| | Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study | Q34257350 |
| | Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach | Q34294997 |
| | Thiazolidinediones | Q34346862 |
| | Results of a reevaluation of cardiovascular outcomes in the RECORD trial | Q34360464 |
| | A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study | Q34421981 |
| | Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database | Q34422144 |
| | Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 |
| | Insulinotropic meglitinide analogues | Q34453173 |
| | Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes | Q34453811 |
| | Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. | Q34509910 |
| | Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta | Q34537980 |
| | Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 |
| | Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance | Q34577169 |
| | A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 |
| | Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | Q34593046 |
| | Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 |
| | Insulin resistance, insulin response, and obesity as indicators of metabolic risk | Q43682653 |
| | Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study | Q43687453 |
| | Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide | Q43834028 |
| | Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians | Q43850960 |
| | Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study | Q44043328 |
| | Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients | Q44110180 |
| | Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. | Q44117925 |
| | Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes | Q44136140 |
| | Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials | Q44143356 |
| | Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart | Q44153403 |
| | Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study | Q44155565 |
| | Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study | Q44155702 |
| | Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics | Q44183858 |
| | Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality | Q44205053 |
| | Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes | Q44231053 |
| | The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study | Q34623719 |
| | Metformin use and mortality among patients with diabetes and atherothrombosis | Q34625337 |
| | Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction | Q34633720 |
| | Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study | Q34644993 |
| | Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 |
| | Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes | Q34692143 |
| | Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study | Q34720231 |
| | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 |
| | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 |
| | Intensive glucose control and macrovascular outcomes in type 2 diabetes. | Q34995674 |
| | Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies | Q34996877 |
| | Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people | Q35004093 |
| | Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality | Q35012749 |
| | The Look AHEAD Trial: A Review and Discussion Of Its Outcomes | Q35116229 |
| | Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therap | Q35178857 |
| | Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes | Q35179865 |
| | Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes | Q35179964 |
| | Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study | Q35235773 |
| | The role of gut hormones in glucose homeostasis | Q35251016 |
| | Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus | Q35345865 |
| | Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications | Q35570243 |
| | Dapagliflozin lowers plasma glucose concentration and improves β-cell function | Q35578244 |
| | Insulin resistance and the effects of thiazolidinediones on cardiac metabolism | Q35609203 |
| | Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus | Q35751679 |
| | Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme | Q35777074 |
| | Extrapancreatic effects of GIP and GLP-1. | Q36012504 |
| | The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit | Q36261162 |
| | Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial | Q36297833 |
| | Mechanisms of beta-cell death in type 2 diabetes. | Q36321520 |
| | Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review | Q36396145 |
| | The place of sulfonylureas in the therapy for type 2 diabetes mellitus | Q36456659 |
| | Cardiovascular biology of the incretin system | Q36484283 |
| | The effects of thiazolidinediones on blood pressure levels - a systematic review | Q36545395 |
| | Impairment of myocardial protection in type 2 diabetic patients | Q44306774 |
| | Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors | Q44442589 |
| | Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin | Q44448309 |
| | Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium | Q44512663 |
| | Thiazolidinediones and blood lipids in type 2 diabetes | Q44542266 |
| | Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes | Q44620317 |
| | Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study | Q44686996 |
| | Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus | Q44759159 |
| | Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 |
| | Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study | Q44802551 |
| | Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes | Q44882775 |
| | Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes | Q44909522 |
| | Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention | Q44912661 |
| | Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. | Q44924385 |
| | Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 |
| | Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus | Q45036323 |
| | beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 |
| | Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 |
| | Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 |
| | Metabolic syndrome: evaluation of pathological and therapeutic outcomes | Q45230909 |
| | Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone | Q45329104 |
| | CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice | Q45810167 |
| | Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control | Q46018332 |
| | Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. | Q46024732 |
| | Chronic insulin administration elevates blood pressure in rats | Q46074981 |
| | Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes | Q46226028 |
| | Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 |
| | Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study | Q46481435 |
| | Dose-response effect of elevated plasma free fatty acid on insulin signaling | Q46513253 |
| | Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). | Q46552257 |
| | A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 |
| | Effect of a multifactorial intervention on mortality in type 2 diabetes | Q46767642 |
| | Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study | Q46773983 |
| | Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure | Q46817496 |
| | Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes | Q46819106 |
| | Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans | Q46919674 |
| | Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial | Q46936072 |
| | Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin | Q46981921 |
| | Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Q47333592 |
| | The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone | Q48271768 |
| | Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. | Q50219055 |
| | Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. | Q50590197 |
| | Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. | Q50798695 |
| | Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. | Q51061297 |
| | Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. | Q51325737 |
| | Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. | Q51334840 |
| | Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. | Q51368060 |
| | Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. | Q51381989 |
| | Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. | Q51468950 |
| | The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. | Q51472360 |
| | Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. | Q51479687 |
| | Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus | Q38085691 |
| | Effects of dapagliflozin on cardiovascular risk factors | Q38113098 |
| | Molecular biology of atherosclerosis | Q38125279 |
| | Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications | Q38197344 |
| | Canagliflozin: a review of its use in patients with type 2 diabetes mellitus | Q38212007 |
| | Mortality risk among sulfonylureas: a systematic review and network meta-analysis | Q38281461 |
| | A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans | Q38490894 |
| | GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. | Q39030156 |
| | Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus | Q39451977 |
| | Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study | Q39518005 |
| | Is insulin atherogenic? | Q39637369 |
| | Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. | Q39648063 |
| | Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study | Q39839307 |
| | A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules | Q39896648 |
| | Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study | Q39942752 |
| | Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression | Q40027585 |
| | Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits | Q40046793 |
| | Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus | Q40102509 |
| | Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia--13-year study | Q41450119 |
| | Effect of insulin on growth of cultured human arterial smooth muscle cells | Q41615238 |
| | Insulin resistance in the vasculature | Q41856477 |
| | Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 |
| | GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice | Q41984767 |
| | Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 |
| | A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes | Q42450726 |
| | Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients | Q42485940 |
| | Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 |
| | In vivo effect of insulin on intracellular calcium concentrations: relation to insulin resistance | Q42527358 |
| | Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression | Q42832873 |
| | Severe hypoglycemia and risks of vascular events and death | Q42868535 |
| | Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome | Q42949053 |
| | Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus | Q43014666 |
| | Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population | Q43046359 |
| | The stunned beta cell: a brief history | Q43073326 |
| | Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion | Q43142618 |
| | Exenatide versus glibenclamide in patients with diabetes | Q43164036 |
| | Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study | Q43181601 |
| | Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure | Q43191785 |
| | Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients | Q43218473 |
| | The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice | Q43231241 |
| | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes | Q43236097 |
| | Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue | Q43237616 |
| | Three-year efficacy of complex insulin regimens in type 2 diabetes | Q43256453 |
| | Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. | Q43409321 |
| | Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury | Q43574002 |
| | Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone | Q43584208 |
| | Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death | Q43596005 |
| | Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 |
| | Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. | Q51486013 |
| | The effect of pioglitazone on the liver: role of adiponectin. | Q51488911 |
| | Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. | Q51495360 |
| | Treatment of familial hypertriglyceridaemia with acarbose. | Q51550714 |
| | Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. | Q51554500 |
| | Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. | Q51556160 |
| | Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. | Q51564567 |
| | Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. | Q51573561 |
| | Insulin resistance and coronary artery disease. | Q51578743 |
| | Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. | Q51581413 |
| | Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 |
| | Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. | Q51600420 |
| | Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. | Q51610700 |
| | Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. | Q51612089 |
| | Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? | Q51615482 |
| | Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. | Q51625510 |
| | Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland | Q51662797 |
| | Relation of plaque lipid composition and morphology to the stability of human aortic plaques. | Q52526775 |
| | Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. | Q52876034 |
| | Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. | Q52961670 |
| | Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 |
| | Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria | Q53998038 |
| | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. | Q54243732 |
| | Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. | Q54539426 |
| | Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs | Q57300672 |
| | Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age | Q57413995 |
| | Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study | Q57563912 |
| | Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic β-cell death in the chronic phase | Q57591412 |
| | Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study | Q57689262 |
| | Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction | Q58447894 |
| | Insulin Sensitivity, Vascular Reactivity, and Clamp-Induced Vasodilatation in Essential Hypertension | Q59297471 |
| P433 | issue | 34 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| | type 2 diabetes | Q3025883 |
| P304 | page(s) | 2288-2296 | |
| P577 | publication date | 2015-06-10 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes | |
| P478 | volume | 36 | |